IBD patients face increased skin cancer risk

November 21, 2011

Certain patients with inflammatory bowel disease (IBD) may have an increased risk of skin cancer, which is intensified by the use of immunosuppressant medications , according to two new studies in Gastroenterology, the official journal of the American Gastroenterological Association. Immunosuppressants are commonly used in the treatment of IBD.

In the first study, researchers found that both past and present exposure to thiopurines (a widely used class of immunosuppressants) significantly increased the risk of nonmelanoma (NMSC) in patients with IBD, even before the age of 50. Currently, there are no specific recommendations for screening for skin cancers in individuals with IBD.

"The of skin cancer that we found in our study was observed in all patients, even before the age of 50 years. As expected, this risk increased with age. All patients with currently receiving or having previously received thiopurines should protect their skin from and receive regular dermatologic screening, regardless of their age," said Laurent Peyrin-Biroulet, MD, PhD, of University Hospital of Nancy, Henri Poincaré University, Vandoeuvre-lès-Nancy, France, and lead author of this study.

NMSC mainly encompasses basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), which are by far the most common cancers diagnosed in North America. NMSC continues to be the most common cancer diagnosed among individuals on immunosuppressive medications; patients with IBD are increasingly treated with these immunosuppressant medications.

In a second study, researchers concluded that certain individuals with IBD, such as men with Crohn's disease, may have a baseline increased risk of BCC, and the use of thiopurines increases the risk of SCC.

"All individuals should be protecting themselves against skin cancer," said Harminder Singh, MD, MPH, FRCPC, of the University of Manitoba and lead author of this study. "But, it is especially important that physicians stress the need to be extra vigilant about skin care with their irritable bowel disease patients, especially among those exposed to immunosuppressants such as thiopurines."

However, Dr. Singh and his colleagues note that the small absolute increased risk of NMSC may not merit stopping thiopurines for those who need them for their IBD disease control.

More information: For more information on IBD, please read the AGA brochure "Understanding Inflammatory Bowel Disease" at www.gastro.org/patient-center/digestive-conditions/inflammatory-bowel-disease

Related Stories

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.